Vandetanib and Bevacizumab in Treating Patients With Advanced Solid Tumors or Lymphoma
This study has been completed.
Information provided by:
National Institutes of Health Clinical Center (CC)
First received: August 13, 2008
Last updated: March 14, 2012
Last verified: March 2012
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Study Completion Date:||February 2011|
|Primary Completion Date:||June 2010 (Final data collection date for primary outcome measure)|
Kummar S, Gutierrez ME, Chen A, Turkbey IB, Allen D, Horneffer YR, Juwara L, Cao L, Yu Y, Kim YS, Trepel J, Chen H, Choyke P, Melillo G, Murgo AJ, Collins J, Doroshow JH. Phase I trial of vandetanib and bevacizumab evaluating the VEGF and EGF signal transduction pathways in adults with solid tumours and lymphomas. Eur J Cancer. 2011 May;47(7):997-1005. doi: 10.1016/j.ejca.2010.12.016. Epub 2011 Jan 17.